Evidence map›Paper›PMID 30761608›Full record

ArticleGlia2019

Independent and cooperative roles of the Mek/ERK1/2-MAPK and PI3K/Akt/mTOR pathways during developmental myelination and in adulthood.

Akihiro Ishii, Miki Furusho, Wendy Macklin, Rashmi Bansal

Open access · greenAbstract read
In one paragraph

Article in Glia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Regulators of Oligodendrocyte Differentiation.Cold Spring Harbor perspectives in biology · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Dopamine D3 Receptor Modulates Akt/mTOR and ERKInternational journal of molecular sciences · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. The role of snare proteins in cortical development.Developmental neurobiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Akihiro IshiiDepartment of Neuroscience, University of Connecticut Medical School, Farmington, Connecticut, USA.
Miki FurushoDepartment of Neuroscience, University of Connecticut Medical School, Farmington, Connecticut, USA.
Wendy MacklinDepartment of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Rashmi BansalDepartment of Neuroscience, University of Connecticut Medical School, Farmington, Connecticut, USA.ORCID 0000-0002-9122-4899
University of Connecticut · USUniversity of Colorado Denver · US

Funding

Fibroblast Growth Factor Receptors in Myelin Function and DiseaseR01NS038878 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BANSAL, RASHMI · 1999 to 2012
$3.9M
Role of FGF-Signaling in MyelinogenesisR37NS038878 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BANSAL, RASHMI · 2013 to 2019
$2.9M
Role of ERK1/ERK2 MAP Kinase in Myelin Assembly and MaintenanceR21NS081948 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BANSAL, RASHMI · 2013 to 2014
$422k
NINDS NIH HHS R01 NS038878NINDS NIH HHS R21 NS081948NINDS NIH HHS R37 NS038878
6 · The paper itself

Abstract

Multiple extracellular and intracellular signals regulate the functions of oligodendrocytes as they progress through the complex process of developmental myelination and then maintain a functionally intact myelin sheath throughout adult life, preserving the integrity of the axons. Recent studies suggest that Mek/ERK1/2-MAPK and PI3K/Akt/mTOR intracellular signaling pathways play important, often overlapping roles in the regulation of myelination. However, it remains poorly understood whether they function independently, sequentially, or converge using a common mechanism to facilitate oligodendrocyte differentiation, myelin growth, and maintenance. To address these questions, we analyzed multiple genetically modified mice and asked whether the deficits due to the conditional loss-of-function of ERK1/2 or mTOR could be abrogated by simultaneous constitutive activation of PI3K/Akt or Mek, respectively. From these studies, we concluded that while PI3K/Akt, not Mek/ERK1/2, plays a key role in promoting oligodendrocyte differentiation and timely initiation of myelination through mTORC1 signaling, Mek/ERK1/2-MAPK functions largely independently of mTORC1 to preserve the integrity of the myelinated axons during adulthood. However, to promote the efficient growth of the myelin sheath, these two pathways cooperate with each other converging at the level of mTORC1, both in the context of normal developmental myelination or following forced reactivation of the myelination program during adulthood. Thus, Mek/ERK1/2-MAPK and the PI3K/Akt/mTOR signaling pathways work both independently and cooperatively to maintain a finely tuned, temporally regulated balance as oligodendrocytes progress through different phases of developmental myelination into adulthood. Therapeutic strategies aimed at targeting remyelination in demyelinating diseases are expected to benefit from these findings.

Indexed as

Age FactorsAnimalsFemaleMaleMAP Kinase Kinase KinasesMAP Kinase Signaling SystemMiceMice, Inbred C57BLMice, TransgenicMyelin SheathNerve Fibers, MyelinatedPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesMAP Kinase Kinase KinasesmTOR protein, mousePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasesdifferentiationmyelinmyelinationmyelinogenesisoligodendrocyte

Identifiers

PMID30761608
PMCPMC6571146
OpenAlexW2912250565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.